Skip to main content

Table 2 Relationship between anti-nucleosome antibody and other disease parameters among patients under study

From: Association of anti-nuclesome and anti C1q antibodies with lupus nephritis in an Egyptian cohort of patients with systemic lupus erythematosus

Variable n (%) or mean ± SD Positive
Anti-nucleosome (n = 49)
Negative
Anti-nucleosome (n = 31)
t/x2 P value
Clinical features Arthritis 42 (85.7) 30 (96.8) 2.581 0.108
Pleurisy 28 (57.1) 14 (45.2) 1.093 0.296
Fever 27 (55.1) 12 (38.7) 2.042 0.153
Malar rash 27 (55.1) 23 (74.2) 2.953 0.086
Oral ulcers 24 (49.0) 14 (45.2) 0.111 0.739
Alopecia 22 (44.9) 12 (38.7) 0.298 0.585
Photosensitivity 15 (30.6) 16 (51.6) 3.528 0.060
Neurologic manifestations 13 (26.5) 7 (22.6) 0.158 0.691
APS 12 (24.5) 7 (22.6) 0.038 0.845
Vasculitis 11 (22.4) 3 (9.7) 2.145 0.143
Pericarditis 8 (16.3) 2 (6.5) 1.693 0.193
Discoid rash 4 (8.2) 2 (6.5) 0.080 0.777
Myositis 1 (2.0) 0 (0.0) 0.641 0.423
Nephritis 24 (49%) 16 (51.6) 2.937 0.230
ECLAM   4.1 ± 2.2 3.3 ± 1.8 1.805 0.075
Laboratory features ESR (mm/1st hour) 51.0 ± 30.7 43.7 ± 29.7 1.051 0.296
Serum creatinine (μmol/L) 0.7 ± 0.3 1.0 ± 0.8 2.110 0.038
Serum albumin (g/dl) 3.8 ± 0.7 4.0 ± 0.7 1.207 0.232
Low C3 < 90 (mg/dl) 25 (51.0) 11 (35.5) 1.852 0.174
Low C4 < 10 (mg/dl) 11 (22.4) 8 (25.8) 0.118 0.731
  1. APS: Antiphospholipid syndrome, ESR: Erythrocyte sedimentation rate, ECLAM: European Consensus Lupus Activity Measurement